Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accuracy, alive, Altera, Alton, Andrew, appointed, appointment, armed, autotaxin, banc, Bausch, behalf, Bio, Breakthrough, Brett, bribery, cardiopulmonary, Carna, CCPA, Christi, Cipla, collateralized, Commissioner, confer, consent, contrary, culture, Delinquent, denial, Dickinson, disagree, dramatically, durable, Eisai, Elipovimab, employer, en, encourage, exit, expropriation, facilitate, flooding, Florida, footnote, Glympse, Goldfinch, Gregg, guideline, heavily, Hoofddorp, HPV, Humanigen, implicit, incremental, iNHL, injury, Insitro, instability, Irish, Johanna, Jyoti, Katie, Kiniksa, Korea, Korean, Kyverna, Lake, lenalidomide, lengthy, Lichtenstein, Lyndra, McHutchison, MCL, Mehra, Mercier, Merdad, NaN, nationwide, Nordisk, Notwithstanding, Novo, Nurix, organizational, Parsey, permanent, Pletcher, pre, prevailed, put, quantitative, RA, recoup, Renown, resold, restate, Robin, Rockefeller, Selgantolimod, Shaw, Shilpa, shorter, specialist, stand, standstill, statutorily, STELLAR, subscription, Sunshine, suspension, taxpayer, terrorism, terrorist, theft, Topline, unrest, upper, variety, Vice, voluntarily, war, Yuhan
Removed:
accrual, Actelion, ADAP, affirmed, aged, Alberta, Apollo, bank, biliary, broker, BTK, burdensome, calcium, calendar, canceled, carboxylase, carcinoma, cardiovascular, ceiling, centralized, characteristic, contacted, conversion, decentralized, decide, declaratory, deduction, discipline, dismissed, distinct, dosage, earning, Ebola, Egypt, embrace, expending, Eyetech, factor, floating, French, German, GlaxoSmithKline, Greece, hepatocellular, improvement, India, integral, invoiced, Iran, JT, labeled, maker, mutual, Mylan, nominee, noncurrent, nonrecurring, Nuc, obligated, perspective, Pfizer, pharmacy, plasma, Portugal, predominantly, principle, promised, recognizing, recover, reducing, refuse, relation, relevance, renew, rental, reserve, resolve, response, revoke, ruled, significance, simplified, Simplifying, staying, suggest, Syk, targeted, terminating, unclean, uncollectible, unenforceable, Virginia, West, whichever, wide, withdrawn
Filing tables
Filing exhibits
- 10-K Annual report
- 4.9 Description of Registrant's Securities
- 10.28 Offer Letter (Hamill)
- 10.29 Severance Agreement (Hamill)
- 21.1 Listing of Subsidiaries
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 CEO Certification
- 31.2 CFO Certification
- 32 Section 906 Certifications
- Download Excel data file
- View Excel data file
Related press release
Associated GILD transcripts
GILD similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-81670, 33-46058, 333-58893, 333-84719, 333-117480, 333-126012, 333-135412, 333-143920, 333-151624, 333-161069, 333-163871, 333-207813, 333-219772 and 333-223248) pertaining to the Employee Stock Purchase Plan, the International Employee Stock Purchase Plan and the 2004 Equity Incentive Plan of Gilead Sciences, Inc., and the Registration Statement on Form S-3 (No. 333-220283) of Gilead Sciences, Inc. and in the related Prospectuses, as applicable, of our reports dated February 24, 2020, with respect to the consolidated financial statements and schedule of Gilead Sciences, Inc., and the effectiveness of internal control over financial reporting of Gilead Sciences, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2019.
/s/ Ernst & Young LLP
San Jose, California
February 24, 2020